-
COSCIENS Biopharma NasdaqCM:CSCI COSCIENS Biopharma Inc., a life science company, engages in developing and commercializing products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, Columbia, the United Kingdom, and internationally. The company lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications. It has a license agreement with NK MEDITECH Ltd. and Er-Kim Pharmaceuticals Bulgaria Eood for the development and commercialization of macimorelin. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Location: 222 Bay Street, Toronto, ON, M5K 1E7, Canada | Website: https://www.cosciensbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-486.8K
Cash
13.76M
Avg Qtr Burn
-3.517M
Short % of Float
0.80%
Insider Ownership
1.52%
Institutional Own.
9.05%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Avenanthramides Tablets (Avs) Details Mild inflammation | Phase 1/2 Data readout | |
Macimorelin (Macrilen®; GHRYVELIN™) Details Pediatric growth hormone deficiency | Failed Discontinued |